Taysha Gene Therapies (TSHA) insider details 889-share stock sale

Rhea-AI Filing Summary

Taysha Gene Therapies insider Frederick Porter plans to sell 889 shares of common stock through Maxim Group on Nasdaq around 02/04/2026, with an aggregate market value of $4,196.08.

The shares were acquired on 02/03/2026 via a vested RSU award, granted in stock as compensation for continued employment. The notice states 273,919,373 shares of common stock outstanding. Over the prior three months, Porter sold 43,003 shares for $204,264.25 and 12,987 shares for $59,870.07.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 06:42 PM Learn about SEC filing dates

FAQ

What insider stock sale is disclosed for TSHA in this notice?

The notice shows insider Frederick Porter plans to sell 889 shares of Taysha Gene Therapies common stock. The planned sale, routed through Maxim Group on Nasdaq, has an aggregate market value of $4,196.08 based on the values listed.

How did the TSHA insider acquire the 889 shares being sold?

The 889 Taysha Gene Therapies shares came from an RSU award acquired on 02/03/2026. The award vested and was settled in stock, with consideration described as the reporting person’s continued service as an employee of the issuer.

What recent TSHA stock sales has Frederick Porter made?

The filing lists two recent sales by Frederick Porter. On 01/23/2026 he sold 43,003 common shares for $204,264.25, and on 01/26/2026 he sold 12,987 common shares for $59,870.07, both identified as Taysha Gene Therapies stock.

How many TSHA shares are reported as outstanding in this notice?

The document reports 273,919,373 shares of Taysha Gene Therapies common stock outstanding. This figure provides a baseline share count alongside the insider’s planned sale of 889 shares and the previously disclosed sales in the last three months.

Which broker and exchange are used for the planned TSHA share sale?

The planned 889-share sale of Taysha Gene Therapies common stock is listed through Maxim Group LLC. The notice identifies Nasdaq as the securities exchange where the shares are expected to be sold, with an approximate sale date of 02/04/2026.

Does the TSHA insider make any representation about undisclosed information?

The signer represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed. The notice also highlights that intentional misstatements or omissions can constitute federal criminal violations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Maxim Group LLC 300 Park Avenue, 16th Floor New York NY 10022	889	4196.08	273919373	02/04/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/03/2026	RSU Award	Issuer			889	02/03/2026	Vested grant settled in stock; consideration was Reporting Person's continued service as an employee of the Issuer.

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Frederick Porter c/o Taysha Gene Therapies, Inc. 3000 Pegasus Park Drive, Suite 1430 Dallas TX 75247	Common Stock	01/23/2026	43003	204264.25
Frederick Porter c/o Taysha Gene Therapies, Inc. 3000 Pegasus Park Drive, Suite 1430 Dallas TX 75247	Common Stock	01/26/2026	12987	59870.07

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)